Laboratorios Farmaceuticos Rovi, S.A. (LON:0ILL)

Market Cap	2.61B +0.3%
Revenue (ttm)	665.66M +3.2%
Net Income	159.46M +40.0%
EPS	3.12 +39.9%
Shares Out	n/a
PE Ratio	16.40
Forward PE	20.32
Dividend	0.67 (1.31%)
Ex-Dividend Date	Jul 13, 2026

Volume	1,296
Open	59.85
Previous Close	59.90
Day's Range	58.80 - 60.50
52-Week Range	52.45 - 87.50
Beta	0.23
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 5, 2026

About LON:0ILL

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Expr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1946
• Employees: 2,470
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0ILL

Financial Performance

In 2025, LON:0ILL's revenue was 743.48 million, a decrease of -2.65% compared to the previous year's 763.75 million. Earnings were 140.44 million, an increase of 2.60%.

Financial numbers in EUR

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 3, 2026

Data Sources Report a data error